Angiogenesis
Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230
Ontarget 2016 May 20 [Epub ahead of print] [Link] Blackwell C, Sherk C, Fricko M, Ganji G, Barnette M, Hoang B, Tunstead J, Skedzielewski T, Alsaid H, Jucker BM, Minthorn E, Kumar R, DeYoung MP. Abstract Fibroblast growth factor (FGF) ligand-dependent signaling has a fundamental role in cancer development and tumor maintenance. GSK3052230 (also known…
Read MoreInhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma
Cancer Research 2016 April 13 [Epub ahead of print] [Link] Takayama Y, Hattori N, Hamada H, Masuda T, Omori K, Akita S, Iwamoto H, Fujitaka K, Kohno N Abstract Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor that secretes various angiogenic factors. The main inhibitor of plasminogen activators, PAI-1 (SERPINE1), has been implicated in…
Read MoreTargeted therapies in malignant pleural mesothelioma: a review of clinical studies
Anticancer Drugs. 2011 Mar;22(3):199-205. [Link] Greillier L, Marco S, Barlesi F. Service d’Oncologie Multidisciplinaire et Innovations Thérapeutiques, Université de la Méditerranée-Assistance Publique Hôpitaux de Marseille, Marseille, France. Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis, whose exposure to asbestos fibers is the main etiology. The incidence of MPM is anticipated to…
Read MoreAntiangiogenic therapies for malignant pleural mesothelioma
Frontiers in Bioscience. 2011 Jan 1;16:740-8. [Link] Yano S, Li Q, Wang W, Yamada T, Takeuchi S, Nakataki E, Ogino H, Goto H, Nishioka Y, Sone S. Division of Medical Oncology, Cancer Research Institute, Kanazawa University. Kanazawa, Ishikawa 920-0934. Abstract Malignant pleural mesothelioma (MPM), arises from the mesothelial cells, is difficult to be diagnosed at…
Read MorePhase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma
Journal of Thoracic Oncology. 2009 Jan;4(1):97-101. [Link] Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA. suresh.ramalingam@emory.edu Abstract Background: Belinostat (PXD 101) is a novel inhibitor of class I and II histone deacetylases. This…
Read MoreA Phase II Trial of Tetrathiomolybdate After Surgery for Malignant Mesothelioma: Final Results
The Annals of Thoracic Surgery. 2008 Aug;86(2):383-9; discussion 390. [Link] Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S. Department of Cardiothoracic Surgery, New York University School of Medicine, New York, New York 10016, USA. harvey.pass@med.nyu.edu Abstract Background: Tetrathiomolybdate (TM) is an oral copper-depleting agent that has been shown to inhibit angiogenesis, and angiogenesis…
Read MoreA pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors
Onkologie. 2008 Jul;31(7):362-5. Epub 2008 Jun 24. [Link] Salzberg M, Kirson E, Palti Y, Rochlitz C. University Hospital Basel, Switzerland. msalzberg@pharmabrains.ch Abstract Background: The transmission of electric fields using insulated electrodes has demonstrated that very low-intensity, properly tuned, intermediate-frequency electric fields, termed tumor-treating fields (TTFields), selectively stunts tumor cell growth and is accompanied by a…
Read MoreThe tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies
Journal of Thoracic Oncology. 2008 Jun;3(6 Suppl 2):S131-4. [Link] Nikolinakos P, Heymach JV. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA. jheymach@mdanderson.org Abstract Cediranib (AZD2171; Recentin, AstraZeneca, Wilmington, Delaware) is a once-daily oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1, 2,…
Read MorePharmacokinetic Analysis of Malignant Pleural Mesothelioma—Initial Results of Tumor Microcirculation and its Correlation to Microvessel Density (CD-34)
Journal of Immunological Methods. 2008 Feb 23 [Epub ahead of print] [Link] Giesel FL, Choyke PL, Mehndiratta A, Zechmann CM, von Tengg-Kobligk H, Kayser K, Bischoff H, Hintze C, Delorme S, Weber MA, Essig M, Kauczor HU, Knopp MV. Radiologie, German Cancer Research Center (DKFZ), INF 280, 69120 Heidelberg, Germany; Ohio State University, Columbus, OH.…
Read MoreBiomarkers for prevention and early diagnosis of malignant pleural mesothelioma
Giornale Italiano di Medicina del Lavoro ed Ergonomia. 2007 Jul-Sep;29(3 Suppl):335-8. [Link] Amati M, Tomasetti M, Scartozzi M, Mariotti L, Ciuccarelli M, Valentino M, Governa M, Santarelli L. Università Politecnica delle Marche, Dipartimento di Patologia Molecolare e Terapie Innovative, Clinica di Medicina del Lavoro, Tronto 10/a, 0020 Torrette, AN. m.amati@univpm.it Abstract Improved detection methods for…
Read More